December 18, 2024

Global Biopharmaceutical M&A and VC Insights

The life sciences industry continues to undergo significant transformation, with companies navigating through portfolio risks, pipeline challenges, public policy, and economic uncertainty. Our latest report reflects on mergers and acquisitions (M&A) trends and venture capital (VC) trends over the past year and provides considerations for biopharmaceutical companies heading into 2025. Discover the key insights below:

M&A activity has been subdued relative to 2023 with companies prioritizing growth and innovation
Acquirers continue to target pre-clinical therapeutics within oncology and central nervous systems (CNS) therapeutic areas
Cell and gene therapies (CGT) and anti-drug conjugates (ADCs) continue to be popular technology targets, with mRNA therapies gaining traction
VC dealmaking continues to remain steady, with 2024 deal volume tracking similarly to 2023
VC deals continue to concentrate around early-stage funding, reflecting a focus on novel innovative technologies
Biotech IPOs in 2024 to date have nearly doubled in volume relative to 2023, indicating acclimation to interest rates generally holding steady

Download the Report

Contact Us.

I acknowledge that A&M will process my personal information in accordance with its Privacy Notice.

Thought Leadership

Where AI Meets Financial Impact

December 8, 2025

CFOs are uniquely positioned to lead the charge on value creation, leveraging emerging technologies to unlock deeper insights and optimise business decisions. This article explores the transformative potential of AI for financial impact and strategic decision-making.

Thought Leadership

M&A commentary: Surge in value of deals

December 3, 2025

The ONS data shows M&A activity Q3 remained low, however, since September we’ve seen an uptick. The market seems to have shrugged off market disruption and restarted in earnest. Mike Trenouth provides comments on the latest data release.

Thought Leadership

A year of recalibration and resilience

December 2, 2025

Private Equity funds have had to be resilient through rising geopolitical tensions, the shock form US tariffs and several years of subdued deal flow and limited exits. But, as 2025 comes to a close, European private equity is showing signs of stability.

Thought Leadership

ASEAN Value Creation Report 2025

November 21, 2025

A&M’s inaugural ASEAN Private Equity Value Creation report provides a deep dive into the pressing challenges facing the industry. We explore the drivers, barriers, and evolving strategies that shape the value creation playbook in the region.

Authors